Showing 1407 results
-
Story / -
Press release /First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intra- and extravascular hemolysis when given as monotherapy in a Phase II study of anti-C5 naïve paroxysmal…
-
Press release /In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average hemoglobin (Hb) level versus baseline in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were…
-
Story /Novel PRC2 inhibitor changes the expression of hundreds of genes in lab model
-
Media Library / -
Press release /NIH study found 58% of patients with treatment-naïve severe aplastic anemia (SAA) achieved a complete response when eltrombopag was given at the initiation of and concurrently with standard…
-
Story /A cellular computing error wreaks havoc on vision.
-
Story /Bioengineers, immunologists and clinicians collaborate to explore a new approach to fighting cancer.
-
Media Library /